



Antibacterial activity of 3,3'-dihydroxycurcumin (DHC) is associated with membrane perturbation

Carlos R. Polaquini^{a,1}, Luana G. Morão^{b,1}, Ana C. Nazaré^a, Guilherme S. Torrezan^a,
Guilherme Dilarri^b, Lúcia B. Cavalca^{b,c}, Débora L. Campos^d, Isabel C. Silva^{b,d}, Jessé A. Pereira^e,
Dirk-Jan Scheffers^c, Cristiane Duque^e, Fernando R. Pavan^d, Henrique Ferreira^{b,*},
Luis O. Regasini^{a,*}

^a Department of Chemistry and Environmental Sciences, Institute of Biosciences, Humanities and Exact Sciences, São Paulo State University (Unesp), São José do Rio Preto 15054-000, Brazil

^b Department of Biochemistry and Microbiology, Institute of Biosciences, São Paulo State University (Unesp), Rio Claro 13506-900, Brazil

^c Department of Molecular Microbiology, Groningen Biomolecular Sciences and Biotechnology Institute, University of Groningen, Groningen 9747, the Netherlands

^d Department of Biological Sciences, School of Pharmaceutical Sciences, São Paulo State University (Unesp), Araraquara 14800-903, Brazil

^e Department of Pediatric Dentistry and Public Health, School of Dentistry, São Paulo State University (Unesp), Aracatuba 16015-050, Brazil

ARTICLE INFO

Keywords:

Curcumin
Curcuminoid
Antibacterial
Antitubercular
Membrane
FtsZ
Bacillus subtilis

ABSTRACT

Curcumin is a plant diphenylheptanoid and has been investigated for its antibacterial activity. However, the therapeutic uses of this compound are limited due to its chemical instability. In this work, we evaluated the antimicrobial activity of diphenylheptanoids derived from curcumin against Gram-positive and Gram-negative bacteria, and also against *Mycobacterium tuberculosis* in terms of MIC (Minimum Inhibitory Concentration) and MBC (Minimum Bactericidal Concentration) values. 3,3'-Dihydroxycurcumin (DHC) displayed activity against *Enterococcus faecalis*, *Staphylococcus aureus* and *M. tuberculosis*, demonstrating MIC values of 78 and 156 µg/mL. In addition, DHC was more stable than curcumin in acetate buffer (pH 5.0) and phosphate buffer (pH 7.4) for 24 h at 37 °C. We proposed that membrane and the cell division protein FtsZ could be the targets for DHC due to that fact that curcumin exhibits this mode of antibacterial action. Fluorescence microscopy of *Bacillus subtilis* stained with SYTO9 and propidium iodide fluorophores indicated that DHC has the ability to perturb the bacterial membrane. On the other hand, DHC showed a weak inhibition of the GTPase activity of *B. subtilis* FtsZ. Toxicity assay using human cells indicated that DHC has moderate capacity to reduce viability of liver cells (HepG2 line) and lung cells (MRC-5 and A549 lines) when compared with doxorubicin. Alkaline comet assay indicated that DHC was not able to induce DNA damage in A549 cell line. These results indicated that DHC is promising compound with antibacterial and antitubercular activities.

1. Introduction

Curcumin is the main diphenylheptanoid from rhizomes of *Curcuma longa*, commonly named as turmeric. It has been considered a privileged natural product due to its therapeutic potential [1]. Its abilities to interact with multiple targets has recognized role in polypharmacology of complex diseases such as cancer and Alzheimer [2]. Additionally, several clinical studies have supported its safety and tolerability for humans [3].

Curcumin has demonstrated a broad spectrum of *in vitro* antibacterial activity against Gram-positive, Gram-negative and

Mycobacteria species [4,5]. *In vivo* investigations showed that curcumin was able to eliminate *Helicobacter pylori* from mice stomach [6] and to decrease the mortality of mice infected with methicillin-sensitive *Staphylococcus aureus* (MSSA) and methicillin-resistant *Staphylococcus aureus* (MRSA) [7]. The mode of antibacterial action of curcumin has been reported as a combination of membrane disruption [8] and cell division blockage [9]. Activity of curcumin on the membrane was attributed to its amphiphilicity, which allows its insertion into phospholipid bilayers, increasing the permeability of membranes [8,10]. The ability of curcumin to perturb bacterial cell division has been attributed to a direct action on FtsZ, a prokaryotic cytoskeleton protein.

* Corresponding authors.

E-mail addresses: henrique.ferreira@linacre.oxon.org (H. Ferreira), luis.regasini@unesp.br (L.O. Regasini).

¹ C.R. Polaquini and L.G. Morão contributed equally to this work.

Curcumin inhibited FtsZ protofilament assembly and enhanced the GTPase activity of this protein by altering its secondary structure [9,11]. The FtsZ polymerization into protofilaments require GTP as a stabilizer and an energy source, leading to the formation of the Z-ring, a pivotal structure in the assembly of the divisome [12].

Although curcumin has shown to be a promising antibacterial agent, its poor chemical stability has not supported advances of its use in clinical and pharmaceutical studies [13,14]. In addition, curcumin exhibits low oral bioavailability due to its poor absorption and extensive intestinal and first-pass metabolism, resulting in rapid excretion [15]. Wang and collaborators described 90% curcumin decomposed rapidly in buffer systems at neutral-basic pH conditions similar to physiological matrices [16]. However, the addition of glutathione, ascorbic acid or phosphate buffer in culture media increased its stability [16]. Interestingly, the presence of human blood also decreased its degradation [16] which may be correlated with effect of plasma proteins, mainly serum albumin and fibrinogen [17]. Thereby, efforts have been made in order to search for more stable analogs [18,19].

In our previous work, curcumin was used as framework to design antibacterial simplified monoketones, which were more active and stable than curcumin [20]. In the current work, we explored the role of substituents on the aromatic rings of curcumin framework, including electron-donating groups (OH, OMe, Me, N(Me)₂ and OAc) and halogens (F, Cl, Br and CF₃) toward antimicrobial activity. We synthesized a series of diphenylheptanoids based on curcumin framework (curcuminoids) and evaluated their antibacterial and antitubercular activities. The chemical stability of most active curcuminoid (DHC) was compared with curcumin in acetate buffer (pH 5.0) and phosphate buffer (pH 7.4) for 24 h at 37 °C. DHC was investigated regarding its effects on the membrane and FtsZ of *Bacillus subtilis*. In order to understand toxicity of DHC toward human cells, cytotoxicity and alkaline comet assays were carried out.

2. Results and discussion

2.1. Chemistry

One-pot synthesis of curcuminoids 1–12 was achieved by Pabon protocol [21], with minor modifications [22]. Reactions between respective benzaldehydes and acetylacetone were performed through successive boron complexes, resulting in yields of 57–95% (Scheme 1). In general, a clear and unambiguous relationship between the stereo-electronic effect of substituents on aromatic ring of benzaldehyde derivatives and reaction yields cannot be established. Ester 13 was synthesized by acetylation of compound 5 using acetic anhydride and pyridine, with yield of 87%.

Structure of curcuminoids was confirmed by their melting point and ¹H and ¹³C Nuclear Magnetic Resonance (NMR) spectral data analyses. Spectra were presented in Supplementary Material. For all curcuminoids, NMR data, including chemical shifts, integrations multiplicities and coupling constants, corresponded to the proposed structures. In ¹H NMR spectrum, aromatic hydrogens were observed as signals in range of δ_{H} 6.50–7.67 ppm. Hydrogens α and β resonated as doublets and clearly indicated the formation of two olefines. Coupling constants values of olefin hydrogens signals ranging from 15 to 16 Hz, corroborating their *trans* configuration. In addition, singlet with resonance at

$\delta_{\text{H}} \sim 5.80$ ppm and integration to one hydrogen was attributed to methyne hydrogen of enol moiety [23].

2.2. Antibacterial and antitubercular activities

The antibacterial and antitubercular activities of curcumin and curcuminoids 1–13 were evaluated against *Enterococcus faecalis*, *Staphylococcus aureus*, *Bacillus subtilis*, *Pseudomonas aeruginosa*, *Escherichia coli* and *Mycobacterium tuberculosis*. Antimicrobial potency was expressed as Minimum Inhibitory Concentration (MIC) and Minimum Bactericidal Concentration (MBC) values in $\mu\text{g}/\text{mL}$. Ciprofloxacin and isoniazid were used as reference antibacterial and antitubercular drugs, respectively (Table 1).


Curcumin displayed activity against *E. faecalis*, *S. aureus* and *B. subtilis*, with MIC values of 78 and 156 $\mu\text{g}/\text{mL}$. However, curcumin demonstrated MIC > 156 $\mu\text{g}/\text{mL}$ against *M. tuberculosis*, *E. coli* and *P. aeruginosa*. Although curcumin has been recognized for its broad antibacterial spectrum, some studies reported that its activity against Gram-positive bacteria has been higher than against Gram-negative species [24,25], corroborating our results. Activity of curcumin against *S. aureus* has been extensively reported. A review about curcumin activity against MSSA strains indicated MIC values ranged from 125 to 256 $\mu\text{g}/\text{mL}$ by using broth microdilution method. These values varied according to strain types and vehicles (DMSO, EtOH or DMF) [26]. In addition, there are studies demonstrating ability of curcumin to reverse methicillin resistance in MRSA [27] and its efficacy against osteomyelitis in rats induced by MRSA, suppressing bacterial growth [28].

First, in order to investigate preliminary relationships between antibacterial/antitubercular activities and substituents on aromatic rings, we compared the activity of curcumin with the unsubstituted curcuminoid (1). Compound 1 was inactive (MIC and MBC values > 156 $\mu\text{g}/\text{mL}$), indicating that substituents OMe and OH at *meta* and *para* positions, respectively, are relevant for antibacterial activity of curcumin against Gram-positive species.

Second, we evaluated the effect of *m*-OMe and *p*-OH separately, testing simplified analogs 3,3'-dimethoxycurcumin (2) and 4,4'-dihydroxycurcumin (3), respectively. Compounds 2 and 3 had MIC and MBC values > 156 $\mu\text{g}/\text{mL}$, suggesting that antibacterial activity of curcumin can be correlated to simultaneous presence of OMe and OH at *meta* and *para* positions, respectively. Also, compound 3 exhibits a natural occurrence in turmeric (also named as bisdesmethoxycurcumin or curcumin III) [14]. Its antibacterial activity was previously studied by Péret-Almeida and co-authors, who reported their inactivity against *S. aureus*, *E. coli* and *Salmonella choleraesuis* [29], corroborating our current findings.

Third, we evaluated two regioisomers of compounds 2 and 3, which were designed by replacement of OMe and OH positions, furnishing 4,4'-dimethoxycurcumin (4) and 3,3'-dihydroxycurcumin (5 or DHC), respectively. Compound 4 was inactive (MIC and MBC values > 156 $\mu\text{g}/\text{mL}$). On the other hand, DHC demonstrated antibacterial activity similar to curcumin against *S. aureus* and *B. subtilis* with MIC values of 156 $\mu\text{g}/\text{mL}$. Furthermore, DHC was more potent than curcumin against *E. faecalis* and *M. tuberculosis* with MIC values of 78 and 156 $\mu\text{g}/\text{mL}$, respectively.

Fourth, we evaluated the effect of other electron-donating groups on aromatic rings, including Me (curcuminoid 6) and N(Me)₂



Scheme 1. One-pot synthesis of curcuminoids 1–12. Ar = phenyl ring substituted by electron-donating groups or electron-withdrawing groups.

Table 1
Antibacterial and antitubercular activities of curcumin and curcuminoids 1–13 expressed as MIC and MBC values in $\mu\text{g/mL}$.

Compound	R	Ef		Sa		Bs		Mt
		MIC	MBC	MIC	MBC	MIC	MBC	MIC
Curcumin	<i>m</i> -OMe, <i>p</i> -OH	156	> 156	156	> 156	78	156	> 156
1	H	> 156	> 156	> 156	> 156	> 156	> 156	> 156
2	<i>m</i> -OMe	> 156	> 156	> 156	> 156	> 156	> 156	> 156
3	<i>p</i> -OH	> 156	> 156	> 156	> 156	> 156	> 156	> 156
4	<i>p</i> -OMe	> 156	> 156	> 156	> 156	> 156	> 156	> 156
DHC or 5	<i>m</i> -OH	78	156	156	> 156	78	156	156
6	<i>p</i> -Me	> 156	> 156	> 156	> 156	> 156	> 156	> 156
7	<i>p</i> -N(Me) ₂	> 156	> 156	> 156	> 156	> 156	> 156	> 156
8	<i>p</i> -F	> 156	> 156	> 156	> 156	> 156	> 156	> 156
9	<i>p</i> -Cl	> 156	> 156	> 156	> 156	> 156	> 156	> 156
10	<i>p</i> -Br	> 156	> 156	> 156	> 156	> 156	> 156	> 156
11	<i>p</i> -CF ₃	> 156	> 156	> 156	> 156	> 156	> 156	> 156
12	<i>m,p</i> -diCl	> 156	> 156	> 156	> 156	> 156	> 156	> 156
13	<i>m</i> -OAc	> 156	> 156	> 156	> 156	> 156	> 156	> 156
Ciprofloxacin	—	0.25	0.25	0.015	0.03	0.015	0.015	—
Isoniazid	—	—	—	—	—	—	—	0.04

MIC = minimal inhibitory concentration; MBC = minimum bactericidal concentration; Ef = *Enterococcus faecalis*; Sa = *Staphylococcus aureus*; Bs = *Bacillus subtilis* and Mt = *Mycobacterium tuberculosis*; — not determined.

(curcuminoid 7), which release electrons by inductive and mesomeric effect, respectively. Curcuminoids 6 and 7 were inactive (MIC and MBC values > 156 $\mu\text{g/mL}$). The comparison among the curcuminoids DHC, 6 and 7 indicated that the electron donation on aromatic rings is not relevant to antibacterial and antitubercular activities. However, the bioactivity seems to be related to acidity of phenol group in DHC, because neutral (Me, curcuminoid 6) and basic (N(Me)₂, curcuminoid 7) groups did not improve antimicrobial potency.

Fifth, we assayed a set of curcuminoids substituted by *p*-F, *p*-Cl, *p*-Br, *p*-CF₃ and *m,p*-diCl (compounds 8 to 12, respectively). All halogenated curcuminoids were not able to inhibit bacterial growth (MIC and MBC values > 156 $\mu\text{g/mL}$), suggesting electron-withdrawing substituents on aromatic rings did not increase antibacterial and antitubercular activities.

In our previous work, we described that diacetylated curcumin (DAC) was more active than curcumin against *Streptococcus mutans*, MSSA and MRSA planktonic and biofilm forms [30,31]. Thus, we hypothesized that the acetylation of DHC could lead to a more potent analog. Unfortunately, ester 13 was inactive (MIC and MBC values > 156 $\mu\text{g/mL}$), corroborating the relevance of acidic OH at *meta* position (phenol moiety) to antibacterial and antitubercular activities. In general, phenolic compounds are recognized for their antibacterial activity [32,33]. Recent studies have elucidated the importance of the hydroxyl group position in phenolic natural product derivatives concerning antibacterial potency, including cinnamylideneacetophenones [34], galates, protocatechuates, gentisates and β -resorcylicates [35].

Curcuminoids 1–13 were not able to inhibit growth of Gram-negative species, including *P. aeruginosa* and *E. coli*. Gram-negative bacteria demonstrate a complex barrier, including two membranes, which makes them less susceptible to antibacterial agents. As part of this barrier, the cell wall exerts central role in the permeation of compounds due to their complex composition (lipopolysaccharides, phospholipids and proteins) [36,37].

We selected DHC for further assays, aiming to evaluate its chemical stability and the elucidation of its molecular targets, which could be related to the mode of antibacterial action exhibited by curcumin. In previous studies by our group, curcumin disrupted the membrane of *B. subtilis*, which was confirmed by microscopy assays. Also, we described that curcumin blocked *B. subtilis* cell division, stimulating the GTPase activity of FtsZ [20].

2.3. Evaluation of DHC chemical stability

Although curcumin is a promising antibacterial agent, its clinical application is limited due to its poor stability under physiological conditions [14]. Thus, chemical stability of DHC was evaluated at pH 5.0 and 7.4 by monitoring the decrease in its UV-Vis absorption at 37 °C and compared with curcumin. As expected, both compounds were more stable under acidic than basic conditions (Fig. 1). Curcumin was rapidly degraded at pH 5.0 and 7.4, reducing 52% and 63% after 24 h, respectively. However, DHC was more stable than curcumin at pH 5.0 and 7.4, reducing only 16% and 24% of its initial concentration after 24 h, respectively. Liu and co-authors also reported a higher stability of DHC when compared with curcumin in RPMI media at 25 °C [38], corroborating our current findings.

Wang and collaborators reported feruloylmethane, vanillin and ferulic acid as degradation compounds of curcumin under phosphate




Fig. 1. Chemical stability of DHC and curcumin at 13.5 $\mu\text{g/mL}$ (pH 5.0 and 7.4) by monitoring the decrease in their maximum absorbance at 37 °C for 24 h. Data are represented as means \pm SEMs and expressed as percentage.

buffer at pH 7.2 (at 37 °C) [16]. These compounds are produced by cleavage of the β -diketone moiety. Thus, stabilizing effects on transition state of these reactions can improve the degradation rate. In this context, curcumin exhibits a hydroxyl group at *para*-position, which resonates to β -diketone moiety, dispersing π -electron density. On the other hand, **DHC** presents a hydroxyl group at *meta*-position, which did not allow that alone electron pairs of hydroxyl group resonate to β -diketone moiety. Thereby, extended conjugation between 4-OH and β -diketone in curcumin structure can be correlated to its degradation. Furthermore, in basic conditions hydroxyl group at *para*-position is deprotonated, facilitating conjugation and degradation of curcumin.

2.4. Effect of **DHC** on the membrane of *B. subtilis*

In order to evaluate the effects of **DHC** on the bacterial membrane, we used *B. subtilis* strain 168. Bacterial cells were exposed to **DHC** at the MIC (78 $\mu\text{g}/\text{mL}$) for 15 and 30 min. Two fluorescent dyes propidium iodide (PI) and SYTO9 were added, which stain cells with damaged membrane (in red) and intact membrane (in blue) [8,39]. Nisin was used as a reference for membrane disruption due to produce membrane pores in *B. subtilis*. Representative fluorescence microscopy images of the negative control (cells treated with 1% DMSO), the positive control (nisin at 5 $\mu\text{g}/\text{mL}$) and **DHC** are shown in Fig. 2. Cells exposed to DMSO and nisin appear labeled in blue and red, respectively. Exposure to **DHC**, in both periods of 15 and 30 min, led to a prevalence of pink-red stained cells, indicating membrane permeability.

Percentages of cells with damaged membrane were quantified from the microscope images and are shown in Fig. 3. Cultures treated with 1% DMSO had approximately 2% of the cells with membrane permeabilized. On the other hand, treatment with nisin demonstrated 99% of the cells stained with PI due to its ability to make pores in the bacterial membrane [40]. Treatment with **DHC** (at the MIC) for 15 min and 30 min displayed damage percentages of 72% and 85%, respectively, evidencing the membrane disruption of *B. subtilis* by **DHC** is time-dependent effect.




Fig. 2. Fluorescence microscopy of *B. subtilis* strain 168 stained with Live/Dead BacLight kit. (A) negative control (cells treated with 1% DMSO); (B) positive control (cells treated nisin at 5 $\mu\text{g}/\text{mL}$, after 30 min) (C) **DHC** (cells treated at MIC, after 15 min); (D) **DHC** (cells treated at MIC, after 30 min). Magnification 100 \times ; bar 5 μm .




Fig. 3. Percentage of permeabilized cells of *B. subtilis*. NC: negative control (cells treated with 1% DMSO); PC: positive control (cells treated with nisin at 5 $\mu\text{g}/\text{mL}$, after 30 min); **DHC** (cells treated at MIC, after 15 and 30 min). *** $p < 0.05$, ANOVA with Dunnett's post-test.

Membranes seems to be a target of phenolic compounds [41,42]. They induce changes in the membrane structure and function, including increased permeability [33,43]. Some antibacterial drugs exhibited the membrane as a primary target such as daptomycin [44] and polymyxin B [45] or a secondary one such as telavancin [46]. Furthermore, the combined use of compounds that increase membrane permeability with other antibacterial agents may be a good alternative against bacterial resistance [47,48].

2.5. Effect of **DHC** on the GTPase activity of *B. subtilis* FtsZ

In order to investigate bacterial division as target of **DHC**, we evaluated its ability to affect the GTPase activity of *Bacillus subtilis* FtsZ (BsFtsZ). Compounds that affect the GTP hydrolysis of FtsZ are promising inhibitors of bacterial division, since GTP and GDP levels

regulate the Z-ring dynamics [49]. We assessed the protein GTP hydrolysis rates during treatment with **DHC** at the MIC (78 µg/mL) and 2 × MIC (156 µg/mL). BsFtsZ was incubated with 1% DMSO and used as negative control. BsFtsZ hydrolysis activity was slightly reduced by **DHC** when compared to the negative control. At the MIC and 2 × MIC values, the percentage of GTPase activity reduction was of 10% and 26%, respectively. Thus, the weak inhibition of bacterial division was less relevant to antibacterial activity than membrane disruption.

2.6. Assessment of **DHC** cyto-genotoxicity and determination of selectivity index

The investigation of new antibacterial agents against eukaryotic cells is an important step for evaluation of their selectivity and safety. Toxicity of **DHC** was evaluated against human cells from liver (tumorigenic HepG2 cell line) and lung (tumorigenic A549 cell and normal MCR-5 cell lines). Hepatocytes are widely used to evaluate the toxicity of bioactive compounds due to biotransformation abilities [50] and lung cells were chosen based on their importance as host site for infections of *E. faecalis*, *S. aureus* and *M. tuberculosis* [51,52]. Toxic effect of curcumin and **DHC** was expressed as the concentration required to reduce the viability of cells at 50% (IC₅₀) (Table 2).

DHC displayed IC₅₀ values ranging from 9.6 to 10.6 µg/mL and it was slightly more toxic than curcumin (15.5 µg/mL ≤ IC₅₀ ≤ 32.3 µg/mL). Biotransformation capacity of hepatocytes did not affect cytotoxicity of **DHC**, because its IC₅₀ value was similar to those of lung cell lines. In addition, no significant difference was observed in the toxic effects of **DHC** against lung lines. Normal human fibroblasts (MCR-5) and adenocarcinoma cells (A549) showed similar sensitivity to **DHC**, indicating altered genes and proteins expression of the tumorigenic lines did not alter the toxicity effect. When compared to doxorubicin (0.03 µg/mL ≤ IC₅₀ ≤ 0.9 µg/mL), a compound known for its cytotoxic properties [53], **DHC** had moderate toxicity against human cells. In order to compare the effect towards prokaryotic cells versus eukaryotic cells, the selectivity indexes (SI) of **DHC** were determined as the ratio between IC₅₀ and MIC values. We used MIC value of 78 µg/mL and IC₅₀ for each human cell line. SI values were of 0.12, 0.13 and 0.12 for HepG2, MRC-5 and A549, respectively. SI values < 1 indicated **DHC** was not selective, displaying higher toxicity against human cells than bacteria.

Several studies have correlated toxicity of curcumin toward human cells to DNA damage, due to its oxidizing properties [54,55]. These effects toward DNA are due to phenolic nature of curcumin and its quinone products, as well as chelatogenic diketone. In order to study genotoxicity of **DHC**, we performed single cell gel electrophoresis assay (alkaline comet assay) with A549 cells, which was the most sensitive line. Comet assay is capable of evaluating damage induced by alkylating, intercalating or oxidizing agents in the DNA of individual cells [56,57]. The DNA of an undamaged nucleus maintains its spherical organization, whereas fragmented DNA migrates across gel (tail) [58]. Hydrogen peroxide (1 mM) was used as reference genotoxic compound due to its strong oxidizing properties and high capacity to induce long comet tail. Lower concentrations than IC₅₀ were used to guarantee high percentages of metabolically viable cells. We selected the

Table 2

Toxicity of curcumin and **DHC** against human cells expressed as IC₅₀ values (in µg/mL).

Compounds	HepG2 (liver)	MRC-5 (lung)	A549 (lung)
DHC	9.8 ± 0.9	10.6 ± 1.4	9.6 ± 0.4
Curcumin	16.9 ± 0.4	15.5 ± 0.8	32.3 ± 2.1
Doxorubicin	0.5 ± 0.08	0.03 ± 0.002	0.9 ± 0.05

IC₅₀ = concentration required to reduce the viability of cells at 50%. HepG2 = liver carcinoma; MRC-5 = normal lung fibroblast; A549 = lung adenocarcinoma.

concentrations referred to ½ IC₅₀ (4.8 µg/mL) and ¼ IC₅₀ (2.4 µg/mL) for **DHC**. Also, curcuminin was evaluated at ½ IC₅₀ (16.2 µg/mL) and ¼ IC₅₀ (8.1 µg/mL).

Tail moment and percentage of DNA in the tail is directly proportional to DNA break [59]. **DHC** demonstrated no significant genotoxic effects compared with the negative control (cells treated with 1% DMSO). Furthermore, the genotoxic parameters of **DHC** were closely similar to curcumin (Fig. 4). Both compounds were three times less able to induce DNA breaks than H₂O₂, indicating weak genotoxic effect toward A549 cell.

3. Conclusion

In conclusion, we synthesized a series of curcuminoids as part of our ongoing search for antibacterial agents based on curcumin structure. 3,3'-Dihydroxycurcumin (**DHC**) was found to be an important hit with antibacterial activity against Gram-positive species and *M. tuberculosis*. The mode of action of **DHC** involved membrane disruption, which is an important target for the development of novel antibacterial agents. Furthermore, preliminary *in vitro* investigations of toxicity and stability indicated that **DHC** is potentially safe and stable at pH 5.0 and 7.4. Altogether, our results corroborate the potential of curcumin as a privileged framework for the discovery of compounds for the treatment of bacterial infections and tuberculosis.

4. Experimental

4.1. Chemistry

4.1.1. Material and instruments

All starting materials and reagents were purchased from Merck. Melting points were determined on a Tecnopon PFM-II® apparatus and were uncorrected. NMR spectra were recorded on two spectrometers: Bruker® Avance III 600 MHz (14.1 T) and Bruker® Avance III 400 MHz (9.4 T). Compounds were dissolved in CDCl₃ or DMSO-*d*₆ and its non-deuterated residue was used as internal standard for establishment of chemical shift values (δ_H and δ_C). ¹H and ¹³C NMR parameters, including δ_H and δ_C, integrations, multiplicities and coupling constants (*J* in Hz) were measured. NMR parameter values were compared to previous descriptions, confirming proposed structures. The ¹H and ¹³C NMR spectra of curcuminoids 1–13 and their detailed analyses are in [Supplementary Material](#).

4.1.2. Synthesis of curcuminoids 1–12

Compounds 1–12 were synthesized by Pabon method [21], according to Venkateswarlu and co-authors [22], with minor modifications. Acetylacetone (5.0 mmol, 0.5 mL) was added to suspension of B₂O₃ (5.0 mmol) in DMF (2.0 mL) and stirred for 15 min at 60 °C. Tributyl borate (10 mmol) was added and stirred for 15 min at 60 °C. Respective benzaldehyde derivatives (10 mmol) was added and stirred for 5 min at 60 °C. Mixture of amylamine (0.1 mL) and acetic acid (0.3 mL) in DMF (1 mL) was added to the reaction and heated to 90 °C for 4 h. After cooling, aqueous solution of acetic acid (20%, 50 mL) was added and stirred for 1 h at 70 °C. Reaction medium was poured onto crushed ice from deionized water. Precipitated crude products were filtered, washed with cold water and dried at room temperature. Compounds 1, 6 and 8–12 were recrystallized in cold ethanol. Compounds 2–5 and 7 were purified by gel filtration column chromatography (LH-20, Sephadex) using ethanol as mobile phase.

4.1.3. Synthesis of curcuminoid 13

Compound 13 was synthesized by acetylation reaction of **DHC** according to Sardi and co-authors [30], with minor modifications [60]. Acetic anhydride (10 mL) was added to a solution of **DHC** (1 mmol) in pyridine (10 mL) and the reaction mixture was kept under magnetic stirring at 100 °C. After 48 h, the residue was partitioned with ethyl




Fig. 4. Genotoxicity of curcumin and DHC against A549 cell line measured by tail moment and percentage of DNA in tail using alkaline comet assay. NC: negative control (cells treated with 1% DMSO); PC: positive control (cells treated with H₂O₂ at 1 mM). ANOVA with Tukey's post-test NC versus treatment. The same letters do not differ significantly at 5% level in comparison to all groups (a), different letters significantly differ at 5% level in comparison to all groups (b).

acetate (3 × 25 mL) and dried at room temperature. The crude product was purified by column chromatography over silica gel using hexane and ethyl acetate (4:1).

4.2. Antibacterial assay

Bacterial species used in this work were *Enterococcus faecalis* (ATCC 51299), *Staphylococcus aureus* (ATCC 14458), *Bacillus subtilis* strain 168, *Pseudomonas aeruginosa* (ATCC 15442) and *Escherichia coli* (ATCC 10536). MIC and MBC values were determined by the broth microdilution method in 96-well microtiter plates, following protocol of National Committee for Clinical Laboratory Standards [61]. Minor modifications in this protocol and their detailed procedures were reported in previous work by Polaquini and co-authors [34]. Stock solutions (at 10 mg/mL) of curcumin and curcuminoids 1–13 were prepared in DMSO and tested in concentrations ranging from 156 to 2.4 µg/mL. Ciprofloxacin was used as a reference antibacterial drug. Three independent assays were performed.

4.3. Antitubercular assay

Antitubercular activity was performed toward *Mycobacterium tuberculosis* H₃₇Rv strain (ATCC 27294). MIC values were determined by Resazurin Microtiter Assay (REMA), following protocol described by Palomino and co-authors [62]. Minor modifications in this protocol and their detailed procedures were reported in previous work by Polaquini and co-authors [34]. Stock solutions (at 10 mg/mL) of curcumin and curcuminoids 1–13 were prepared in DMSO and tested in concentrations ranging from 156 to 2.4 µg/mL. Isoniazid was used as reference antitubercular drug. Three independent assays were performed.

4.4. Chemical stability assay

Stability of DHC (at λ_{max} 398 nm) and curcumin (at λ_{max} 426 nm) was assessed by monitoring their UV-visible absorptions in acetate buffer (pH 5.0) and phosphate buffer (pH 7.4) at 37 °C [19,38]. Compounds were solubilized in DMSO and evaluated at 13.5 µg/mL. The spectra were run against blanks containing buffer solution and DMSO.

4.5. Membrane perturbation assay

The membrane disruption assay was performed as described by Morão and co-authors [20]. The analysis was carried out with the Live/Dead BacLight Bacterial Viability kit (Thermo-Scientific L7012). All analyses were performed at 15 and 30 min. All pictures were taken

using an Olympus BX-61 microscope equipped with an OrcaFlash-2.8 monochromatic camera (Hamamatsu) and guided by the CellSens software version 11. Experiments were performed in triplicates, and the quantification analyses considered at least 200 individuals (n = 200) per treatment.

4.6. Anti-FtsZ assay

FtsZ of *Bacillus subtilis* (BsFtsZ) was expressed and purified using the ammonium sulfate precipitation method as described previously [63]. The BsFtsZ GTP hydrolysis rate was determined using the malachite green phosphate assay described by Król and co-authors [63] with minor modifications. Stocks of DHC at MIC and 2 × MIC with FtsZ (24 µM), MgCl₂ (20 mM) and Triton X-100 (0.02%) prepared in polymerization buffer (Hepes 50 mM, KCl 300 mM, pH 7.5) were stabilized at 30 °C for 5 min. Then, GTP (2 mM) dissolved in the polymerization buffer was added in different time points (the final concentrations were half of the stock solutions). The reactions were kept at 30 °C and developed in accordance with MAK307 (Sigma-Aldrich®) kit. 1% DMSO was used as negative control.

4.7. Cytotoxicity assay

The toxicity against human cells was evaluated according to Silva and co-authors [64]. The cell lines used were HepG2 (human liver carcinoma cell line ATCC HB-8065), MRC-5 (normal human lung fibroblast cell line ATCC CCL-171) and A549 (human lung adenocarcinoma epithelial cell line ATCC CCL-185). For the cytotoxicity assay, 2.5 × 10⁴ cells/mL were seeded into a 96-well cell culture plate with a total volume of 100 µL for 24 h. Cells were treated with curcumin and DHC in concentrations ranging from 0.8 to 100 µg/mL. After 24 h incubation, the medium was removed, and 50 µL of resazurin (0.01% w/v) was added to each well, and the plates were incubated at 37 °C for 3 h. The absorbance was measured with a microplate reader in which an excitation (530 nm) and an emission (590 nm) filters were used. Three independent assays were performed. IC₅₀ value that represents the concentration required to reduce the viability of cells at 50% was calculated from an analytical curve through a regression analysis. Doxorubicin was used as reference cytotoxic drug.

4.8. Genotoxicity assay

The genotoxicity of curcumin and DHC was evaluated using the alkaline version of the comet assay (single cell gell electrophoresis) by Tice and co-authors protocol [56], with minor modifications [64]. For

the comet assay, 2.5×10^4 A549 cells/well were seeded and treated with DHC and curcumin in concentrations at $\frac{1}{2}$ IC₅₀ and $\frac{1}{4}$ IC₅₀ values for 24 h. After resuspending the cells, the following steps of the assay were carried out: (i) the microscope slides were coated with normal-melting-point agarose; (ii) the treated cell suspension was transferred to a microcentrifuge tube; (iii) 20 μ L cells were suspended in 100 μ L of a 0.5% low-melting agarose solution at 37 °C; (iv) 100 μ L of this suspension were placed on the slides, which had been kept in freezer for 5 min. In summary, 100 μ L cells were taken, homogenized with low-melting point agarose, spread on microscope slides, which were pre-coated with normal-melting-point agarose and covered with a coverslip. After 5 min at 4 °C, the coverslip was removed from the slides and they were immersed in cold lysing solution (2.4 M NaCl; 100 mM EDTA; 10 mM Tris, 10% DMSO and 1% Triton-X, pH 10) for 24 h. After the lysis, the slides were placed in electrophoresis chamber, covered with electrophoresis buffer (300 mM NaOH plus 1 mM EDTA, pH > 13) and left for 20 min for DNA to unwind. The electrophoresis ran for 20 min (25 V and 300 mA), after which slides were submerged for 15 min in neutralization buffer (0.4 M Tris-HCl, pH 7.5) and fixed in ethanol. Duplicate slides were stained with SYBR Green and 50 cells per sample were screened in fluorescent microscope equipped with excitation filter of 515–560 nm, barrier filter of 590 nm and objective (magnification \times 40). The level of DNA damage was assessed by image analysis system (TriTek CometScore™ 1.5, 2006) and the percentage of DNA in the tail and tail moment were calculated. The results were expressed as the mean \pm standard error of three independent experiments performed in duplicate.

Declaration of Competing Interest

The authors declare no conflict of interest.

Acknowledgments

The authors gratefully acknowledge financial support from the Coordination for the Improvement of Higher Education Personnel (CAPES, finance code 001), Brazilian Council for Scientific and Technological Development (CNPq) (Grants 471129/2013-5, 306251/2016-7 and 429322/2018-6), the São Paulo Research Foundation (FAPESP) (Grants 2013/50367-8, 2015/08089-6, 2015/50162-2, 2017/50216-0 and 2018/15083-2), the Netherlands Organization for Scientific Research (NWO, 729.004.005) and Multiuser Centre for Biomolecular Innovation (FAPESP 2009/53989-4). CRP thanks National Institute of Science and Genomics Technology for Citrus Improvement (INCT Citrus) and CAPES (finance code 001) for his scholarships (Grants FAPESP 2014/50880-0 and CNPq 465440/2014-2).

Appendix A. Supplementary material

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.bioorg.2019.103031>.

References

- [1] A.S. Oliveira, E. Sousa, M. Helena-Vasconcelos, M. Pinto, Curcumin: a natural lead for potential new drug candidates, *Curr. Med. Chem.* 22 (2015) 4196–4232, <https://doi.org/10.2174/0929867322666151029104611>.
- [2] F. Cavaleri, W. Jia, The true nature of curcumin's polypharmacology, *J. Prev. Med.* 2 (2017) 1–11, <https://doi.org/10.21767/2572-5483.100015>.
- [3] C.D. Lao, M.T. Ruffin, D. Normolle, D.D. Heath, S.I. Murray, J.M. Bailey, M.E. Boggs, J. Crowell, C.L. Rock, D.E. Brenner, Dose escalation of a curcuminoid formulation, *BMC Complement Altern. Med.* 6 (2006) 1–4, <https://doi.org/10.1186/1472-6882-6-10>.
- [4] S.Z. Moghadamtousi, H.A. Kadir, P. Hassandarvish, H. Tajik, S. Abubakar, K. Zandi, A review on antibacterial, antiviral, and antifungal activity of curcumin, *BioMed Res. Int.* 2014 (2014) 1–12, <https://doi.org/10.1155/2014/186864>.
- [5] E. Marini, M.D. Giulio, G. Magi, S.D. Lodovico, M.E. Cimarelli, A. Brenciani, A. Nostro, L. Cellini, B. Facinelli, Curcumin, an antibiotic resistance breaker against a multiresistant clinical isolate of *Mycobacterium abscessus*, *Phytother. Res.* 32 (2018) 488–495, <https://doi.org/10.1002/ptr.5994>.
- [6] R. De, P. Kundu, S. Swarnakar, T. Ramamurthy, A. Chowdhury, G.B. Nair, A.K. Mukhopadhyay, Antimicrobial activity of curcumin against *Helicobacter pylori* isolates from India and during infections in mice, *Antimicrob. Agents Chemother.* 53 (2009) 1592–1597, <https://doi.org/10.1128/AAC.01242-08>.
- [7] J. Wang, X. Zhou, W. Li, X. Deng, Y. Deng, X. Niu, Curcumin protects mice from *Staphylococcus aureus* pneumonia by interfering with the self-assembly process of α -hemolysin, *Sci. Rep.* 6 (2016) 1–12, <https://doi.org/10.1038/srep28254>.
- [8] P. Tyagi, M. Singh, H. Kumari, A. Kumari, K. Mukhopadhyay, Bactericidal activity of curcumin I is associated with damaging of bacterial membrane, *PLoS ONE* 10 (2015) e0121313, <https://doi.org/10.1371/journal.pone.0121313>.
- [9] D. Rai, J.K. Singh, N. Roy, D. Panda, Curcumin inhibits FtsZ assembly: an attractive mechanism for its antibacterial activity, *Biochem. J.* 410 (2008) 147–155, <https://doi.org/10.1042/BJ20070891>.
- [10] G.K. Varshney, R.K. Saini, P.K. Gupta, K. Das, Effect of curcumin on the diffusion kinetics of a hemicyanine dye, LDS-698, across a lipid bilayer probed by second harmonic spectroscopy, *Langmuir* 29 (2013) 2912–2918, <https://doi.org/10.1021/la304778d>.
- [11] S. Kaur, N.H. Modi, D. Panda, N. Roy, Probing the binding site of curcumin in *Escherichia coli* and *Bacillus subtilis* FtsZ – A structural insight to unveil antibacterial activity of curcumin, *Eur. J. Med. Chem.* 45 (2010) 4209–4214, <https://doi.org/10.1016/j.ejmech.2010.06.015>.
- [12] X. Yang, Z. Lyu, A. Miguel, R. McQuillen, K.C. Huang, J. Xiao, GTPase activity–coupled treadmilling of the bacterial tubulin FtsZ organizes septal cell wall synthesis, *Science* 355 (2017) 744–747, <https://doi.org/10.1126/science.aak9995>.
- [13] M. Heger, R.F. van Golen, M. Broekgaarden, M.C. Michel, The molecular basis for the pharmacokinetics and pharmacodynamics of curcumin and its metabolites in relation to cancer, *Pharmacol. Rev.* 66 (2014) 222–307, <https://doi.org/10.1124/pr.110.004044>.
- [14] K.M. Nelson, J.L. Dahlin, J. Bisson, J. Graham, G.F. Pauli, M.A. Walters, The essential medicinal chemistry of curcumin: miniperspective, *J. Med. Chem.* 60 (2017) 1620–1637, <https://doi.org/10.1021/acs.jmedchem.6b00975>.
- [15] R.A. Sharma, A.J. Gescher, W.P. Steward, Curcumin: the story so far, *Eur. J. Cancer* 41 (2005) 1955–1968, <https://doi.org/10.1016/j.ejca.2005.05.009>.
- [16] Y.J. Wang, M.H. Pan, A.L. Cheng, L.I. Lin, Y.S. Ho, C.Y. Hsieh, J.K. Lin, Stability of curcumin in buffer solutions and characterization of its degradation products, *J. Pharm. Biomed. Anal.* 15 (1997) 1867–1876, [https://doi.org/10.1016/S0731-7085\(96\)02024-9](https://doi.org/10.1016/S0731-7085(96)02024-9).
- [17] M.H.M. Leung, T.W. Kee, Effective stabilization of curcumin by association to plasma proteins: human serum albumin and fibrinogen, *Langmuir* 25 (2009) 5773–5777, <https://doi.org/10.1021/la804215v>.
- [18] S. Jayakumar, R.S. Patwardhan, D. Pal, D. Sharma, S.K. Sandur, Dimethoxycurcumin, a metabolically stable analogue of curcumin enhances the radiosensitivity of cancer cells: possible involvement of ROS and thioredoxin reductase, *Biochem. Biophys. Res. Commun.* 478 (2016) 446–454, <https://doi.org/10.1016/j.bbrc.2016.06.144>.
- [19] Z.S. Tu, Q. Wang, D.D. Sun, F. Dai, B. Zhou, Design, synthesis, and evaluation of curcumin derivatives as Nrf2 activators and cytoprotectors against oxidative death, *Eur. J. Med. Chem.* 134 (2017) 72–85, <https://doi.org/10.1016/j.ejmech.2017.04.008>.
- [20] L.G. Morão, C.R. Polaquini, M. Kopacz, G.S. Torrezan, G.M. Ayusso, G. Dilari, L.B. Cavalca, A. Zielińska, D.J. Scheffers, L.O. Regasini, H. Ferreira, A simplified curcumin targets the membrane of *Bacillus subtilis*, *MicrobiologyOpen* 8 (2019) e00683, <https://doi.org/10.1002/mbo3.683>.
- [21] H.J.J. Pabon, A synthesis of curcumin and related compounds, *Recl. Trav. Chim. Pays Bas* 83 (1964) 379–386, <https://doi.org/10.1002/recl.19640830407>.
- [22] S. Venkateswarlu, M.S. Ramachandra, G.V. Subbaraju, Synthesis and biological evaluation of polyhydroxycurcuminoids, *Bioorg. Med. Chem.* 13 (2005) 6374–6380, <https://doi.org/10.1016/j.bmc.2005.06.050>.
- [23] L.M. Deck, L.A. Hunsaker, T.A.V. Jagt, L.J. Whalen, R.E. Royer, D.L.V. Jagt, Activation of anti-oxidant Nrf2 signaling by enone analogues of curcumin, *Eur. J. Med. Chem.* 143 (2018) 854–865, <https://doi.org/10.1016/j.ejmech.2017.11.048>.
- [24] Y. Wang, Z. Lu, H. Wu, F. Lv, Study on the antibiotic activity of microcapsule curcumin against foodborne pathogens, *Int. J. Food Microbiol.* 136 (2009) 71–74, <https://doi.org/10.1016/j.ijfoodmicro.2009.09.001>.
- [25] R.K. Basniwal, H.S. Buttar, V.K. Jain, N. Jain, Curcumin nanoparticles: preparation, characterization, and antimicrobial study, *J. Agric. Food Chem.* 59 (2011) 2056–2061, <https://doi.org/10.1021/jf104402t>.
- [26] S.Y. Teow, K. Liew, S.A. Ali, A.S.B. Khoo, S.C. Peh, Antibacterial action of curcumin against *Staphylococcus aureus*: a brief review, *J. Trop. Med.* 2016 (2016) 1–10, <https://doi.org/10.1155/2016/2853045>.
- [27] S.H. Mun, S.B. Kim, R. Kong, J.G. Choi, Y.C. Kim, D.W. Shin, O.H. Kang, D.Y. Kwon, Curcumin reverse methicillin resistance in *Staphylococcus aureus*, *Molecules* 19 (2014) 18283–18295, <https://doi.org/10.3390/molecules19118283>.
- [28] Z. Zhou, C. Pan, Y. Lu, Y. Gao, W. Liu, P. Yin, X. Yu, Combination of erythromycin and curcumin alleviates *Staphylococcus aureus* induced osteomyelitis in rats, *Front. Cell Infect. Microbiol.* 7 (2017) 1–6, <https://doi.org/10.3389/fcimb.2017.00379>.
- [29] L. Péret-Almeida, C.C. Naghetini, E.A. Nunan, R.G. Junqueira, M.B.A. Glória, *In vitro* antimicrobial activity of the ground rhizome, curcuminoid pigments and essential oil of *Curcuma longa* L., *Ciênc. Agrotec.* 32 (2008) 875–881, <https://doi.org/10.1590/S1413-70542008000300026>.
- [30] J.C.O. Sardi, C.R. Polaquini, I.A. Freires, L.C.C. Galvão, J.G. Lazarini, G.S. Torrezan, L.O. Regasini, P.L. Rosalen, Antibacterial activity of diacetylcurcumin against *Staphylococcus aureus* results in decreased biofilm and cellular adhesion, *J. Med. Microbiol.* 66 (2017) 816–824, <https://doi.org/10.1099/jmm.0.000494>.

- [31] C.V.G. Sanches, J.C.O. Sardi, R.S.S. Terada, J.G. Lazarini, I.A. Freires, C.R. Polaquini, G.S. Torrezan, L.O. Regasini, M. Fujimaki, P.L. Rosalen, Diacetylcurcumin: a new photosensitizer for antimicrobial photodynamic therapy in *Streptococcus mutans* biofilms, *Biofouling* 35 (2019) 340–349, <https://doi.org/10.1080/08927014.2019.1606907>.
- [32] S. Makwana, R. Choudhary, J. Haddock, P. Kohli, *In vitro* antibacterial activity of plant based phenolic compounds for food safety and preservation, *Lebensm. Wiss. Technol.* 62 (2015) 935–939, <https://doi.org/10.1016/j.lwt.2015.02.013>.
- [33] A.M. Pisoschi, A. Pop, C. Georgescu, V. Turcuş, N.K. Olah, E. Mathe, An overview of natural antimicrobials role in food, *Eur. J. Med. Chem.* 143 (2018) 922–935, <https://doi.org/10.1016/j.ejmech.2017.11.095>.
- [34] C.R. Polaquini, G.S. Torrezan, V.R. Santos, A.C. Nazaré, D.L. Campos, L.A. Almeida, I.C. Silva, H. Ferreira, F.R. Pavan, C. Duque, L.O. Regasini, Antibacterial and anti-tubercular activities of cinnamylideneacetophenones, *Molecules* 22 (2017) 1685, <https://doi.org/10.3390/molecules22101685>.
- [35] A.C. Nazaré, C.R. Polaquini, L.B. Calvaca, D.B. Anselmo, M.F.C. Saiki, D.A. Monteiro, A. Zielinska, P. Rahal, E. Gomes, D.J. Scheffers, H. Ferreira, L.O. Regasini, Design of antibacterial agents: alkyl dihydroxybenzoates against *Xanthomonas citri* subsp. *citri*, *Int. J. Mol. Sci.* 19 (2018) 3050, <https://doi.org/10.3390/ijms19103050>.
- [36] H.I. Zgurskaya, C.A. López, S. Gnanakaran, Permeability barrier of Gram-negative cell envelopes and approaches to bypass it, *ACS Infect. Dis.* 1 (2015) 512–522, <https://doi.org/10.1021/acscinfed.5b00097>.
- [37] N.M. Nass, S. Farooque, C. Hind, M.E. Wand, C.P. Randall, J.M. Sutton, R.F. Seipke, C.M. Rayner, A.J. O'Neill, Revisiting unexploited antibiotics in search of new antibacterial drug candidates: the case of γ -actinorhodin, *Sci. Rep.* 7 (2017) 1–11, <https://doi.org/10.1038/s41598-017-17232-1>.
- [38] G.Y. Liu, Y.Z. Sun, N. Zhou, X.M. Du, J. Yang, S.J. Guo, 3,3'-OH curcumin causes apoptosis in HepG2 cells through ROS-mediated pathway, *Eur. J. Med. Chem.* 112 (2016) 157–163, <https://doi.org/10.1016/j.ejmech.2016.02.019>.
- [39] L. Boulos, M. Prevost, B. Barbeau, J. Coallier, R. Desjardins, LIVE/DEAD[®] BacLight[™]: application of a new rapid staining method for direct enumeration of viable and total bacteria in drinking water, *J. Microbiol. Methods* 37 (1999) 77–86, [https://doi.org/10.1016/S0167-7012\(99\)00048-2](https://doi.org/10.1016/S0167-7012(99)00048-2).
- [40] Z. Sun, P. Li, F. Liu, H. Bian, D. Wang, X. Wang, Y. Zou, C. Sun, W. Xu, Synergistic antibacterial mechanism of the *Lactobacillus crispatus* surface layer protein and nisin on *Staphylococcus saprophyticus*, *Sci. Rep.* 7 (2017) 1–12, <https://doi.org/10.1038/s41598-017-00303-8>.
- [41] B. Das, D. Mandal, S.K. Dash, S. Chattopadhyay, S. Tripathy, D.P. Dolai, S.K. Dey, S. Roy, Eugenol provokes ROS-mediated membrane damage-associated antibacterial activity against clinically isolated multidrug-resistant *Staphylococcus aureus* strains, *Infect. Dis. (Auckl)* 9 (2016) 11–19, <https://doi.org/10.4137/IDRT.S31741>.
- [42] S. Wang, J. Yao, B. Zhou, J. Yang, M.T. Chaudry, M. Wang, F. Xiao, Y. Li, W. Yin, Bacteriostatic effect of quercetin as an antibiotic alternative *in vivo* and its antibacterial mechanism *in vitro*, *J. Food Prot.* 81 (2017) 68–78, <https://doi.org/10.4315/0362-028X.JFP-17-214>.
- [43] R. Gyawali, S.A. Ibrahim, Natural products as antimicrobial agents, *Food Control* 46 (2014) 412–429, <https://doi.org/10.1016/j.foodcont.2014.05.047>.
- [44] M.T. Lee, W.C. Hung, M.H. Hsieh, H. Chen, Y.Y. Chang, H.W. Huang, Molecular state of the membrane-active antibiotic daptomycin, *Biophys. J.* 113 (2017) 82–90, <https://doi.org/10.1016/j.bpj.2017.05.025>.
- [45] A.P. Zavascki, L.Z. Goldani, J. Li, R.L. Nation, Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review, *J. Antimicrob. Chemother.* 60 (2007) 1206–1215, <https://doi.org/10.1093/jac/dkm357>.
- [46] J.A. Karlowsky, K. Nichol, G.G. Zhanel, Telavancin: mechanisms of action, *in vitro* activity, and mechanisms of resistance, *Clin. Infect. Dis.* 61 (2015) S58–S68, <https://doi.org/10.1093/cid/civ534>.
- [47] K. Akilandeswari, K. Ruckmani, Synergistic antibacterial effect of apigenin with β -lactam antibiotics and modulation of bacterial resistance by a possible membrane effect against methicillin resistant *Staphylococcus aureus*, *Cell. Mol. Biol.* 62 (2016) 74–82, <https://doi.org/10.14715/cmb/2016.62.14.13>.
- [48] H. Chi, H. Holo, Synergistic antimicrobial activity between the broad spectrum bacteriocin garvicin KS and nisin, farnesol and polymyxin B against Gram-positive and Gram-negative bacteria, *Curr. Microbiol.* 75 (2018) 272–277, <https://doi.org/10.1007/s00284-017-1375-y>.
- [49] P.W. Groundwater, R. Narlawar, V.W.Y. Liao, A. Bhattacharya, S. Srivastava, K. Kunal, M. Daddareddy, P.M. Oza, R. Mamidi, E.C.L. Marrs, J.D. Perry, D.E. Hibbs, D. Panda, A carbocyclic curcumin inhibits proliferation of Gram-positive bacteria by targeting FtsZ, *Biochemistry* 56 (2017) 514–524, <https://doi.org/10.1021/acs.biochem.6b00879>.
- [50] M.J. Gómez-Lechón, L. Tolosa, M.T. Donato, Upgrading HepG2 cells with adenoviral vectors that encode drug-metabolizing enzymes: application for drug hepatotoxicity testing, *Expert Opin Drug Metab. Toxicol.* 13 (2017) 137–148, <https://doi.org/10.1080/17425255.2017.1238459>.
- [51] V. Savini, G. Gherardi, D. Astolfi, E. Polilli, G. Dicuonzo, C. D'amario, P. Fazii, D. D'antonio, Insights into airway infections by enterococci: A review, *Recent Pat. Antiinfect. Drug Discov.* 7 (2012) 36–44, <https://doi.org/10.2174/157489112799829774>.
- [52] M. Schwerdt, C. Neumann, B. Schwartzbeck, S. Kampmeier, S. Herzog, D. Görlich, A. Dübbbers, J. Große-Onnebrink, C. Kessler, P. Küster, H. Schültingkemper, J. Treffon, G. Petters, B.C. Kahl, *Staphylococcus aureus* in the airways of cystic fibrosis patients - A retrospective long-term study, *Int. J. Med. Microbiol.* 308 (2018) 631–639, <https://doi.org/10.1016/j.ijmm.2018.02.003>.
- [53] M. Mohajeri, A. Sahebkar, Protective effects of curcumin against doxorubicin-induced toxicity and resistance: A review, *Crit. Rev. Oncol. Hematol.* 122 (2018) 30–51, <https://doi.org/10.1016/j.critrevonc.2017.12.005>.
- [54] J. Cao, L. Jia, H.M. Zhou, Y. Liu, L.F. Zhong, Mitochondrial and nuclear DNA damage induced by curcumin in human hepatoma G2 cells, *Toxicol. Sci.* 91 (2006) 476–483, <https://doi.org/10.1093/toxsci/kfj153>.
- [55] C.Y. Ting, H.E. Wang, C.C. Yu, H.C. Liu, Y.C. Liu, I.T. Chian, Curcumin triggers DNA damage and inhibits expression of DNA repair proteins in human lung cancer cells, *Anticancer Res.* 35 (2015) 3867–3873.
- [56] R.R. Tice, E. Agurell, D. Anderson, B. Burlinson, A. Hartmann, H. Kobayashi, Y. Miyamae, E. Rojas, J.C. Ryu, Y.F. Sasaki, Single cell gel/comet assay: Guidelines for *in vitro* and *in vivo* genetic toxicology testing, *Environ. Mol. Mutagen.* 35 (2000) 206–221, [https://doi.org/10.1002/\(SICI\)1098-2280\(2000\)35:3<206::AID-EM8>3.0.CO;2-J](https://doi.org/10.1002/(SICI)1098-2280(2000)35:3<206::AID-EM8>3.0.CO;2-J).
- [57] V. Gunasekaran, G.V. Raj, P. Chand, A comprehensive review on clinical applications of comet assay, *J. Clin. Diagn. Res.* 9 (2015) 1–5, <https://doi.org/10.7860/JCDR/2015/12062.5622>.
- [58] D. Cappoen, V. Majce, C. Uythethofken, D. Urnkar, V. Mathys, M. Kočevar, L. Verschaeve, S. Polanc, K. Huygen, J. Košmrlj, Biological evaluation of diazene derivatives as anti-tubercular compounds, *Eur. J. Med. Chem.* 74 (2014) 85–94, <https://doi.org/10.1016/j.ejmech.2013.12.057>.
- [59] A. Azqueta, A.R. Collins, The essential comet assay: a comprehensive guide to measuring DNA damage and repair, *Arch. Toxicol.* 87 (2013) 949–968, <https://doi.org/10.1007/s00204-013-1070-0>.
- [60] A. Savietto, C.R. Polaquini, M. Kopacz, D.J. Scheffers, B.C. Marques, L.O. Regasini, H. Ferreira, Antibacterial activity of monoacetylated alkyl gallates against *Xanthomonas citri* subsp. *citri*, *Arch. Microbiol.* 200 (2018) 929–937, <https://doi.org/10.1007/s00203-018-1502-6>.
- [61] P.A. Wayne, NCCLS: National Committee for Clinical Laboratory Standards. *Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically*; Approved Standard, 5th ed., CLSI Document M7-A5; National Committee for Clinical Laboratory Standards, Wayne, PA, USA, 2002.
- [62] J.C. Palomino, A. Martin, M. Camacho, H. Guerra, J. Swings, F. Portaels, Resazurin microtiter assay plate: simple and inexpensive method for detection of drug resistance in *Mycobacterium tuberculosis*, *Antimicrob. Agents Chemother.* 46 (2002) 2720–2722, <https://doi.org/10.1128/AAC.46.8.2720-2722.2002>.
- [63] E. Król, D.J. Scheffers, FtsZ polymerization assays: Simple protocols and considerations, *J. Vis. Exp.* 81 (2013) 50844, <https://doi.org/10.3791/50844>.
- [64] I.C. Silva, C.R. Polaquini, L.O. Regasini, H. Ferreira, F.R. Pavan, Evaluation of cytotoxic, apoptotic, mutagenic, and chemopreventive activities of semi-synthetic esters of gallic acid, *Food Chem. Toxicol.* 105 (2017) 300–307, <https://doi.org/10.1016/j.fct.2017.04.033>.